Étiquette : publi

Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.

Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.

Chauffour, A., Morel, F., Reibel, F., Petrella, S., Mayer, C., Cambau, E. and Aubry, A. (2021). A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clinical Microbiology and Infection 27, 1601–1612, http://doi.org/10.1016/j.cmi.2021.07.007.

Ortuño-Gutiérrez, N., Mzembaba, A., Ramboarina, S., Andriamira, R., Baco, A., Braet, S., Younoussa, A., Cauchoix, B., Salim, Z., Amidy, M., Grillone, S., Rasamoelina, T., Cambau, E., Geluk, A., de Jong, B. C., Richardus, J. H. and Hasker, E. (2021). Exploring clustering of leprosy in the Comoros and Madagascar: A geospatial analysis. International Journal of Infectious Diseases 108, 96–101, http://doi.org/10.1016/j.ijid.2021.05.014.

Rousset, L., Sokal, A., Vignon-Pennamen, M.-D., Pagis, V., Rybojad, M., Lecorche, E., Mougari, F., Bagot, M., Bouaziz, J.-D. and Jachiet, M. (2020). Association d’une lèpre borderline tuberculoïde et d’une tuberculose : un cas et revue de la littérature. Annales de Dermatologie et de Vénéréologie 147, 886–891, http://doi.org/10.1016/j.annder.2020.09.571.

Avanzi, C., Lécorché, E., Rakotomalala, F. A., Benjak, A., Rapelanoro Rabenja, F., Ramarozatovo, L. S., Cauchoix, B., Rakoto-Andrianarivelo, M., Tió-Coma, M., Leal-Calvo, T., Busso, P., Boy-Röttger, S., Chauffour, A., Rasamoelina, T., Andrianarison, A., Sendrasoa, F., Spencer, J. S., Singh, P., Dashatwar, D. R., Narang, R., Berland, J.-L., Jarlier, V., Salgado, C. G., Moraes, M. O., Geluk, A., Randrianantoandro, A., Cambau, E. and Cole, S. T. (2020). Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00711 [Accessed March 2022].

Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: https://www.santepubliquefrance.fr/import/epidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017 [Accessed February 2022].

Cambau, E., Saunderson, P., Matsuoka, M., Cole, S. T., Kai, M., Suffys, P., Rosa, P. S., Williams, D., Gupta, U. D., Lavania, M., Cardona-Castro, N., Miyamoto, Y., Hagge, D., Srikantam, A., Hongseng, W., Indropo, A., Vissa, V., Johnson, R. C., Cauchoix, B., Pannikar, V. K., Cooreman, E. a. W. D., Pemmaraju, V. R. R., Gillini, L., Kriswamati, A., Al-Samie, A. R., Issoufou, A., Tiendrebeogo, A., Kingalu, A., Randrianantoandro, A., Kumar, A., Chauffour, A., Win, A. A., Pandey, B., Agrawal, C. M., Widaningrum, C., Schmotzer, C., Kafando, C., Bhandari, C. M., Sema, C., Vidanagama, D. S., Scollard, D. M., Beyene, D., Morelo, E. F., Kassa, E. D., Ramarolahy, E. B., Claco, E., Villalon, E. E., Sidibe, F., Sakho, F., Abdoulaye, F., Guilengue, F. F., Gajete, F., Babu, G. R., Moussa, G., Thakur, G. D., Cabanos, G., Sock, G., Clugston, G., Zaidy, H., Watanabe, H., Kawuma, H. J., Mallari, I. B., Goulart, I. M. B., Ahamed, I., Subbanna, J., Houzeo, J. G., Luengu, J. N. M., Bertolli, J., Lloyd-Owen, J., Matheu, J., Brunelli, J. P., Alzate, J. C. B., Neupane, Kapil Dev, Osuga, K., Yamaguchi, K., Azam, K., Lin, K. M., Momoudu, K., Kyaw, K., Bide, L., Doanh, L. H., My, L. H., Shah, M., Kodio, M., Sidibe, M., Ebenezer, M., Grossi, M. A. de F., Balagon, M. F., Canlonon, M., Makino, M., Htoo, M. M., Ahmed, M. J., Nadine, M.-M., Roferos, F. O., Krismawati, H., Thida, M., Htoon, M. T., Neupane, K. D., Phuc, N. H. N., Van, N. H., Hai, N. P. N., Ishii, N., Soe, O., Amiel, O., Tossou, O., Konare, O., Joshi, P. L., Rao, P. V. R., Krishnamurthy, P., Brennan, P. J., Busso, P., Bhatia, R., Andrianarivelo, M. R., Ramdas, D. R., Chabi, R., Gusmao, R., DjupuriIzwardy, R., Soares, R. C. F. R., Jhadav, R., Buhrer, S., Cho, S.-N. R., Jianping, S., Lzumi, S., Barua, S., Chaitanya, S., Tiendrebeogo, S. M. R., Khang, T. H., Gillis, T. P., Mori, T., Vijayalakshmi, V., Kamara, V. D., Wei, W., Smith, W. C. S., Li, W., Lew, W., Al-Qubati, Y., Suzuki, Y. and Nanba, Y. (2018). Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection 24, 1305–1310, http://doi.org/10.1016/j.cmi.2018.02.022.

Chauffour, A., Lecorche, E., Reibel, F., Mougari, F., Raskine, L., Aubry, A., Jarlier, V. and Cambau, E. (2018). Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clinical Microbiology and Infection 24, 1213.e5-1213.e8, http://doi.org/10.1016/j.cmi.2018.06.004.

Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. and Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. BMC Infectious Diseases 18, 506, http://doi.org/10.1186/s12879-018-3402-4.

Cambau, E. (2018). Antileprosy drugs: mode of action and mechanisms. In: International textbook of leprosy, URL: https://internationaltextbookofleprosy.org/chapter/anti-leprosy-drugs-modes-action-and-mechanisms-resistance-mycobacterium-leprae [Accessed May 2022].

Machado, D., Lecorche, E., Mougari, F., Cambau, E. and Viveiros, M. (2018). Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front Microbiol 9, http://doi.org/10.3389/fmicb.2018.03072.

Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172, http://doi.org/10.1016/j.cmi.2016.09.006.

Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369, http://doi.org/10.1155/2016/4632369.

Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46, http://doi.org/10.1186/s40249-016-0140-y.

Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.

Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.

Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.

Veziris, N., Chauffour, A., Escolano, S., Henquet, S., Matsuoka, M., Jarlier, V. and Aubry, A. (2013). Resistance of M. leprae to Quinolones: A Question of Relativity? PLoS Negl Trop Dis 7, e2559, http://doi.org/10.1371/journal.pntd.0002559.

Gomez, C., Ponien, P., Serradji, N., Lamouri, A., Pantel, A., Capton, E., Jarlier, V., Anquetin, G. and Aubry, A. (2013). Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry 21, 948–956, http://doi.org/10.1016/j.bmc.2012.12.011.

Cambau, E., Chauffour-Nevejans, A., Tejmar-Kolar, L., Matsuoka, M. and Jarlier, V. (2012). Detection of Antibiotic Resistance in Leprosy Using GenoType LepraeDR, a Novel Ready-To-Use Molecular Test. PLoS Negl Trop Dis 6, e1739, http://doi.org/10.1371/journal.pntd.0001739.

Matrat, S., Cambau, E., Jarlier, V. and Aubry, A. (2008). Are All the DNA Gyrase Mutations Found in Mycobacterium leprae Clinical Strains Involved in Resistance to Fluoroquinolones? Antimicrob Agents Chemother 52, 745–747, http://doi.org/10.1128/AAC.01095-07.

Honoré, N., Roche, P. W., Grosset, J. H. and Cole, S. T. (2001). A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev 72, 441–448, http://doi.org/10.5935/0305-7518.20010052.

Grosset, J. H. and Cole, S. T. (2001). Genomics and the chemotherapy of leprosy. Lepr Rev 72, 429–440, http://doi.org/10.5935/0305-7518.20010051.

Grosset, J. H. (2001). Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69, S14-18.

Nguyen, L. N., Cartel, J. L. and Grosset, J. H. (2000). Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 71 Suppl, S33-35; discussion S35-36, http://doi.org/10.5935/0305-7518.20000064.

Ji, B. and Grosset, J. (2000). Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 71 Suppl, S81-87, http://doi.org/10.5935/0305-7518.20000074.

Consigny, S., Bentoucha, A., Bonnafous, P., Grosset, J. and Ji, B. (2000). Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother 44, 2919–2921, http://doi.org/10.1128/AAC.44.10.2919-2921.2000.

Ji, B. and Grosset, J. H. (1999). Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis 67, S45-55.

Ji, B., Sow, S., Perani, E., Lienhardt, C., Diderot, V. and Grosset, J. (1998). Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 42, 1115–1120, http://doi.org/10.1128/AAC.42.5.1115.

Ji, B., Jamet, P., Sow, S., Perani, E. G., Traore, I. and Grosset, J. H. (1997). High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 41, 1953–1956, http://doi.org/10.1128/AAC.41.9.1953.

Mane, I., Cartel, J. L. and Grosset, J. H. (1997). Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis 65, 224–229.

Grosset, J. (1997). Whither short-course chemotherapy for leprosy? Indian J Lepr 69, 119–120.

Ji, B., Levy, L. and Grosset, J. H. (1996). Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int J Lepr Other Mycobact Dis 64, S80-88; discussion S88-90.

Ji, B., Jamet, P., Perani, E. G., Sow, S., Lienhardt, C., Petinon, C. and Grosset, J. H. (1996). Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 40, 2137–2141, http://doi.org/10.1128/AAC.40.9.2137.

Ji, B., Perani, E. G., Petinom, C. and Grosset, J. H. (1996). Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 40, 393–399, http://doi.org/10.1128/AAC.40.2.393.

Ji, B., Perani, E. G., Petinom, C., N’Deli, L. and Grosset, J. H. (1994). Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 38, 662–667, http://doi.org/10.1128/AAC.38.4.662.

Xiong, J. H., Ji, B., Perani, E. G., Pétinon, C. and Grosset, J. H. (1994). Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis 62, 37–42.

Honoré, N., Perrani, E., Telenti, A., Grosset, J. and Cole, S. T. (1993). A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis 61, 600–604.

Ji, B., Jamet, P., Perani, E. G., Bobin, P. and Grosset, J. H. (1993). Powerful Bactericidal Activities of Clarithromycin and Minocycline against Mycobacterium leprae in Lepromatous Leprosy. J Infect Dis 168, 188–190, http://doi.org/10.1093/infdis/168.1.188.

Ji, B., Perani, E. G., Petinon, C. and Grosset, J. H. (1992). Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 60, 556–561.

Ji, B., Perani, E. G. and Grosset, J. H. (1991). Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 35, 579–581, http://doi.org/10.1128/AAC.35.3.579.

Ji, B. and Grosset, J. (1991). Ofloxacin for the treatment of leprosy. Acta Leprol 7, 321–326.

Chanteau, S., Cartel, J. L., Perani, E., N’Deli, L., Roux, J. and Grosset, J. H. (1990). Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Lepr Rev 61, 330–340, http://doi.org/10.5935/0305-7518.19900030.

Ji, B. and Grosset, J. H. (1990). Recent advances in the chemotherapy of leprosy. Lepr Rev 61, 313–329, http://doi.org/10.5935/0305-7518.19900029.

Grosset, J. H., Ji, B. H., Guelpa-Lauras, C. C., Perani, E. G. and N’Deli, L. N. (1990). Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58, 281–295.

N’Deli, L., Guelpa-Lauras, C. C., Perani, E. G. and Grosset, J. H. (1990). Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58, 12–18.

Grosset, J. H., Guelpa-Lauras, C. C., Perani, E. G. and Beoletto, C. (1988). Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis 56, 259–264.

Grosset, J., Guelpa-Lauras, C. C., Millan, J., Bodian, M. and Perani, E. (1987). [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)]. Med Trop (Mars) 47, 171–175.

Guelpa-Lauras, C. C., Perani, E. G., Giroir, A. M. and Grosset, J. H. (1987). Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis 55, 70–77.

Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S.-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S., Osei Mireku, S., Abotsi, J., Adu Poku, J. K., Asamoah-Frimpong, R., Osei-Wusu, B., Sarpong, E., Konadu, B., Opoku, E., Forson, M., Ndogyele, M., Ofori, E., Aboagye, F., Berko, T., Amofa, G., Nsiah, A., Mensah-Bonsu, J., Ofori Nyarko, J., Amoako, Y. A., Koranteng Tannor, E., Boakye-Appiah, J., Dzibordzi Loglo, A., Sarpong-Duah, M., Agbavor, B., Ardent, M. F., Yamadjako, A., Adanmado Gersande, N., Adeye, A., Kindjinou, M., Akpolan, Kiki, M., Sodjinou, E., Guegnard, C., Klis, S.-A., Velding, K., Omansen, T., Ofori-Adjei, D., Eyangoh, S., Knell, A. and Faber, W. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet 395, 1259–1267, http://doi.org/10.1016/S0140-6736(20)30047-7.

Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. and Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14, e0007857, http://doi.org/10.1371/journal.pntd.0007857.

Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370, http://doi.org/10.1038/s41467-018-07804-8.

Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.

Ruf, M.-T., Schütte, D., Chauffour, A., Jarlier, V., Ji, B. and Pluschke, G. (2012). Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrob Agents Chemother 56, 687–696, http://doi.org/10.1128/AAC.05543-11.

Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Cambau, E. and Herrmann, J.-L. (2010). Les Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses, L’Encyclopédie Médico-chirurgicale.

Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M. and Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 53, 2955–2959, http://doi.org/10.1128/AAC.00011-09.

Ji, B., Chauffour, A., Robert, J. and Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 52, 1912–1916, http://doi.org/10.1128/AAC.00193-08.

Ji, B., Chauffour, A., Robert, J., Lefrançois, S. and Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 51, 3737–3739, http://doi.org/10.1128/AAC.00730-07.

Lefrançois, S., Robert, J., Chauffour, A., Ji, B. and Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob Agents Chemother 51, 645–650, http://doi.org/10.1128/AAC.00821-06.

Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot, C. and Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50, 1921–1926, http://doi.org/10.1128/AAC.00052-06.

Dega, H., Bentoucha, A., Robert, J., Jarlier, V. and Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 46, 3193–3196, http://doi.org/10.1128/AAC.46.10.3193-3196.2002.

Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V. and Grosset, J. (2001). Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 45, 3109–3112, http://doi.org/10.1128/AAC.45.11.3109-3112.2001.

Dega, H., Robert, J., Bonnafous, P., Jarlier, V. and Grosset, J. (2000). Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 44, 2367–2372, http://doi.org/10.1128/AAC.44.9.2367-2372.2000.